About Us
Company Overview
Our Leadership
Global Supply Chain
IP Protection
Quality & Compliance
Environmental, Health and Safety
Solutions and Services
Discovery Synthesis
GMP Services
Generic APIs
FTE Services
Regulatory Affairs
Peptide Synthesis Service
Oligonucleotide Synthesis
Cosmetic Peptides
GMP Manufacturing
GMP Production Capacity
GMP Compliance & Certification
Leuprorelin Acetate
Triptorelin Acetate
Triptorelin Pamoate
Goserelin Acetate
Cetrorelix Acetate
Exenatide Acetate
Semaglutide
Terlipressin Acetate
Teduglutide
Linaclotide
Difelikefalin
Resources Center
FAQ
White Paper
Video
News
Company News
Blog
Careers
Contact Us
Catalog Peptides
US Operation
WHAT ARE YOU LOOKING FOR?
Home
About Us
About Us
Company Overview
Our Leadership
Global Supply Chain
IP Protection
Quality & Compliance
Environmental, Health and Safety
Solutions and Services
Solutions and Services
Discovery Synthesis
GMP Services
Generic APIs
FTE Services
Regulatory Affairs
Resources Center
Resources Center
FAQ
White Paper
Video
News
News
Company News
Blog
Careers
Contact Us
Catalog Peptides
US Operation
Email Us
Search
Search
Home
Catalog Peptides
CARTS
CARTS
CART-001A
CART (55-76), rat
Ile-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val(Cys14&Cys20 bridge)
CART-001B
CART (55-76), rat
Ile-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val(Cys14&Cys20)
CART-002A
CART (55-102), rat
Ile-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-Cys-Asp-Cys-Pro-Arg-Gly-Thr-Ser-Cys-Asn-Ser-Phe-Leu-Leu-Lys-Cys-Leu(Cys20&Cys40 bridge , Cys14&Cys32 bridge , Cys34&Cys47 bridge)
CART-002B
CART (55-102), rat
Ile-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-Cys-Asp-Cys-Pro-Arg-Gly-Thr-Ser-Cys-Asn-Ser-Phe-Leu-Leu-Lys-Cys-Leu(Cys20&Cys40 bridge , Cys14&Cys32 bridge , Cys34&Cys47 bridge)
CART-003A
CART (62-76), rat, human
Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val(Cys68&Cys74 bridge)
CART-003B
CART (62-76), rat, human
Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val(Cys7&Cys13 bridge)
CART-004A
CART (55-102), human
Val-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-Cys-Asp-Cys-Pro-Arg-Gly-Thr-Ser-Cys-Asn-Ser-Phe-Leu-Leu-Lys-Cys-Leu(Cys20&Cys40 bridge , Cys14&Cys32 bridge , Cys34&Cys47 bridge)
CART-004B
CART (55-102), human
Val-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-Cys-Asp-Cys-Pro-Arg-Gly-Thr-Ser-Cys-Asn-Ser-Phe-Leu-Leu-Lys-Cys-Leu(Cys20&Cys40 bridge , Cys14&Cys32 bridge , Cys34&Cys47 bridge)
CART-005A
CART (62-102), human, rat
Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-Cys-Asp-Cys-Pro-Arg-Gly-Thr-Ser-Cys-Asn-Ser-Phe-Leu-Leu-Lys-Cys-Leu(Cys13&Cys33 bridge , Cys7&Cys25 bridge , Cys27&Cys40 bridge)
CART-005B
CART (62-102), human, rat
Tyr-Gly-Gln-Val-Pro-Met-Cys-Asp-Ala-Gly-Glu-Gln-Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-Cys-Asp-Cys-Pro-Arg-Gly-Thr-Ser-Cys-Asn-Ser-Phe-Leu-Leu-Lys-Cys-Leu(Cys13&Cys33 bridge , Cys7&Cys25 bridge , Cys27&Cys40 bridge)
Chinese Peptide Updates
30
Nov
2023
Emerging Trends in CGMP Peptide Manufacturing for Therapeutic Breakthroughs
Understanding the Importance of CGMP Peptides in Biopharmaceuticals
Nov 16, 2023
Exhibition review | Chinese Peptide company attended the 3rd China Polypeptide Industry Conference
Oct 11, 2023
The 8th CPC Symposiun on Peptide and Oligonucleotide Therapeutics was successfully concluded
Oct 10, 2023
86-571-86737011
Your browser does not support VBScript!
